BRAF and melanoma: The vaccine-like effect of lysosomal inhibition observed in a controlled laboratory environment may or may not translate into the clinic, but it could explain why some patients treated with dabrafenib, trametinib, and HCQ in previously treated BRAF mutant melanoma had such a deep and durable response this regimen (32).